Dr. Ayman M. Noreddin

Dr. Noreddin received his Ph.D. in Pharmaceutical Sciences from the University of the Pacific, California and received research training as a visiting scholar at the Department of Medicine, Stanford University. He had postdoctoral fellowship (Pharmacokinetics and Pharmacodynamics of Antimicrobials), Department of Medical Microbiology, University of Manitoba followed by an American College of Clinical Pharmacy postdoctoral fellowship (Infectious Diseases). Dr. Noreddin’s research interest includes Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy, clinical simulation and Monte Carlo analysis and bacterial resistance in biofilm studies. Dr. Noreddin has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions

Research Interests

  • Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy
  • Clinical simulation and Monte Carlo analysis
  • Bacterial resistance in biofilm studies
  • Cancer epigenetic studies
  • Minority health care studies

Research Focus

  • Anti-infective translational research in relation to antimicrobial resistance: Our goal is to improve patient care by maximizing clinical outcomes and preventing the development of bacterial resistance.
  • Anti-Cancer translational research in relation to 3D modeling and epigenetic studies: Our goal is to optimize cancer chemotherapy and overcome/reverse the development of resistance
  • Approach taken by my research program is defined by both bench investigations as well as clinical simulation studies:
  • In-Vitro Pharmacokinetic/Pharmacodynamic(PK/PD) modeling of anti-infective therapy
  • Cutting edge in-vitro pharmacodynamic modeling techniques (for both planktonic as well as biofilm growing cells) are utilized to mimic concentration-time profile and populations encountered in patients. Our goal is to design strategies that optimize anti-infective efficacy and prevent the selection of drug resistant mutants during anti-infective therapy.
  • In-Vitro Pharmacokinetic/Pharamcodynamic(PK/PD) modeling of cancer chemotherapy Advanced 3D cell culture models to evaluate administration schedules for anti-cancer agents and epigenetic studies to optimize clinical outcome.
  • Mathematical modeling and clinical simulation analysis
  • This translational approach involves integration of pre-clinical pharmacokinetic/pharmacodynamic data as well as early clinical pharmacokinetics/population pharmacokinetics data into mathematical modeling and Monte Carlo simulation routines. Our goal is to elucidate exposure-response relationship for target identification and optimal design of clinical trials.